Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

Avapritinib

NAVIGATOR

Blueprint Medicines · Phase 1 · Completed · Enrollment 250

NCT02508532

ArmPopulationDoseEstimandComparatorEfficacy
Avapritinib 300 or 400 mg, PDGFRA exon 18unresectable or metastatic GIST with PDGFRA exon 18 mutation (n = 43)300 or 400 mgSingle armn/roverall response rate (independent review): 84%, median follow up 10.6 months
Avapritinib, PDGFRA D842V subgroupPDGFRA D842V (n = 38)300 or 400 mgSingle armn/roverall response rate (independent review): 89%, median follow up 10.6 months
Avapritinib, all GIST safety populationGIST, 267 patients in intracranial hemorrhage pooled count300 or 400 mgSingle armn/rn/r